California State Teachers Retirement System Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW)

California State Teachers Retirement System grew its position in Edwards Lifesciences Co. (NYSE:EW) by 0.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 935,928 shares of the medical research company’s stock after acquiring an additional 178 shares during the quarter. California State Teachers Retirement System owned about 0.16% of Edwards Lifesciences worth $69,287,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $26,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the 4th quarter valued at about $30,000. Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $54,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $76.28 on Wednesday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a market cap of $44.84 billion, a PE ratio of 10.94, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The business has a 50-day simple moving average of $70.99 and a two-hundred day simple moving average of $71.20.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the business posted $0.66 EPS. Edwards Lifesciences’s revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares in the company, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. The trade was a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock worth $5,163,062 over the last three months. 1.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research note on Friday, April 25th. Finally, Morgan Stanley raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $79.45.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.